Sharapova's drugs suspension reduced
Appeals court cuts it to 15 months
Tested positive for meldonium in January
Maria Sharapova’s tennis career will resume sooner than expected.
The five-time grand slam champion has had her two-year drugs ban reduced to 15 months by the Court of Arbitration for Sport (CAS), meaning she will be back in time for the French Open in May 2017.
Sharapova tested positive for banned substance meldonium at the Australian Open in January and was subsequently banned for two years by the International Tennis Federation (ITF).
But CAS has shaved nine months off that original verdict, meaning Sharapova is eligible to compete again on April 26.
“The panel found that Ms. Sharapova committed an anti-doping rule violation and that while it was with “no significant fault,” she bore some degree of fault, for which a sanction of 15 months is appropriate,” CAS said Tuesday in a statement on its official website.
Sharapova immediately expressed her relief at the reduction of her ban, and took aim at the ITF, saying she hoped it would learn from this experience.
“I’ve gone from one of the toughest days of my career last March when I learned about my suspension to now, one of my happiest days, as I found out I can return to tennis in April,” she said in a statement Tuesday.
“In so many ways, I feel like something I love was taken away from me and it will feel really good to have it back. Tennis is my passion and I have missed it. I am counting the days until I can return to the court. I have learned from this, and I hope the ITF has as well. CAS concluded that “the panel has determined it does not agree with many of the conclusions of the (ITF) Tribunal.”
She went on to justify her use of meldonium, which is also known as mildronate.
“I have taken responsibility from the very beginning for not knowing that the over-the-counter supplement I had been taking for the last 10 years was no longer allowed. But I also learned how much better other federations were at notifying their athletes of the rule change, especially in Eastern Europe where mildronate is commonly taken by millions of people,” the Russian said.
Her legal team provided a list of examples of other sports where ruling bodies had provided warnings about this year’s change in status of meldonium.
“Now that this process is over, I hope the ITF and other relevant tennis anti-doping authorities will study what these other federations did, so that no other tennis player will have to go through what I went through,” Sharapova added.
“And to my fans, I thank you so much for living and breathing so many of these tough months together. During this time, I have learned the true meaning of a fan and I am so fortunate to have had your support. I’m coming back soon and I can’t wait.”
Tennis world stunned
The sport was plunged into shock in March when Sharapova announced at a Los Angeles press conference she had failed a drugs test. A provisional ban was announced by the ITF shortly after.
Sharapova said she was first prescribed meldonium, also known as mildronate, in 2006 for heart issues and was unaware it had been added to the banned substance list by the World Anti-Doping Agency (WADA) as of January 1.
She acknowledged taking it before each match she played at the Australian Open as she was knocked out of the tournament at the quarterfinal stage by her nemesis Serena Williams.
Handing down the two-year ban, an independent panel appointed by the ITF ruled Sharapova hadn’t used meldonium as a vehicle for cheating but stated the former world No. 1 was “the sole author of her misfortune.”
But Sharapova insisted: “The ITF tribunal unanimously concluded that what I did was not intentional. The tribunal found that I did not seek treatment from my doctor for the purpose of obtaining a performance enhancing substance.
“The ITF spent tremendous amounts of time and resources trying to prove I intentionally violated the anti-doping rules and the tribunal concluded I did not.”
The two-year ban is in line with non-specified substances such as meldonium for first-time offenders who aren’t deemed to have intentionally cheated. The ITF had sought a four-year punishment.
Sharapova, who was this year unseated as the world’s richest female athlete by Serena Williams after 11 years at the top, announced instantly she would be appealing to CAS.
She claimed she had been taking meldonium since 2006 for heart issues, a magnesium deficiency and because her family has a history of diabetes.
Meldonium was added to the prohibited list “because of evidence of its use by athletes with the intention of enhancing performance,” WADA said on its website.
Potential benefits include boosting endurance and aiding the recovery process, though Sharapova’s lawyers produced statements from doctors denying the drug aids performance.
Sharapova took meldonium before matches but never declared it on doping control forms, including at the Australian Open this year.
She tested positive five times for meldonium in 2015 – but not during the period when she reached the Australian Open final after winning a Brisbane warmup event. Her defense team said she forgot to take it and other drugs she used at tournaments (magnerot and riboxin) with her Down Under on that occasion.
Sharapova said she simply failed to read an email that stated meldonium would be added to the banned list on January 1 this year. In evidence heard during the tribunal it was stated her IMG agent Max Eisenbud also failed to check.
Eisenbud was the sole member of her current entourage who knew she was taking the drug – not her coach Sven Groeneveld, physiotherapist or nutritionist – the panel heard.
Sharapova, who has continued to promote her candy company Sugarpova since being suspended, had hoped to fast track proceedings at CAS in a bid to make the Rio Olympics.
With the ITF she had agreed to an ”expedited procedure” which was due to see CAS’s verdict delivered in July. But CAS moved that back to September to give both parties more time.
In the wake of the revelations racket provider Head stood by her, but other sponsors distanced themselves, including watch maker Tag Heuer. Despite the ruling, Nike backed Sharapova.
If she hadn’t managed to reduce the sanction, Sharapova’s ban would have ended on January 25, 2018.